文献速递认知障碍与痴呆

阿尔茨海默病生物标志物检测及全疾病连续过程中的结果告知

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
PubMed 文献 · Neurology · 2023-01-31

本文针对阿尔茨海默病(AD)生物标志物检测结果告知需求,基于临床与研究经验、伦理法律及文献,提出五步告知法:评估检测适宜性、检测前教育与知情同意、实施检测、向受试者及支持者告知结果、随访促进健康。

要点

  • AD生物标志物检测结果告知需评估个体适宜性后再进行。
  • 检测前应提供教育并获取受试者及支持者的知情同意。
  • 告知结果后需随访以促进受试者健康。

核心结论

  • 作者提出五步法指导AD生物标志物检测结果的告知,以回应临床与研究中日益增长的告知需求。

研究设计与样本

  • 本文为基于临床与研究经验、现有证据、伦理法律及文献的方法学建议。

主要发现

  • AD特征性病理过程包括β-淀粉样蛋白、过度磷酸化tau蛋白和神经变性。

关键数值与推荐

  • 第一步:确定AD生物标志物检测及结果告知对特定患者或研究参与者是否适宜。
  • 若检测适宜,第二步:提供检测前教育并向个体及其支持者获取检测知情同意。
  • 第三步:实施检测。
  • 第四步:向个体及其支持者告知结果。
  • 第五步:随访以促进受试者健康。

临床怎么用

  • 临床医生可按五步法框架向患者或研究参与者告知AD生物标志物检测结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Three pathologic processes are characteristic of Alzheimer disease (AD): β-amyloid, hyperphosphorylated tau, and neurodegeneration. Our understanding of AD is undergoing a transformation due to our ability to measure biomarkers of these processes across different stages of cognitive impairment. There is growing interest in using AD biomarker tests in care and research and, with this, a growing need for guidance on how to return these sensitive results to patients and participants. Here, we propose a 5-step approach informed by clinical and research experience designing and implementing AD biomarker disclosure processes, extant evidence describing how individuals react to AD biomarker information, ethics, law, and the literature on breaking bad news. The clinician should (1) determine the appropriateness of AD biomarker testing and return of results for the particular patient or research participant. If testing is appropriate, the next steps are to (2) provide pretest education and seek consent for testing from the individual and their support person, (3) administer testing, (4) return the results to the individual and their support person, and (5) follow-up to promote the recipient's well-being.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Largent EA, Grill JD, O'Brien K, et al. Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum. Neurology. 2023. PMID: 36720642. doi:10.1212/WNL.0000000000206891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。